FEATURED ARTICLES

• Start Fast, Scale Seamlessly: Why A Different Oncology Model Was Needed

  Oncology programs don’t lose momentum because the science fails, but because execution fractures as complexity grows. Learn how continuity-first operating models help sponsors move faster.

• Keeping Oncology Programs Moving As Complexity Increases

  As oncology trials grow more complex, speed depends on clarity. Consistent oversight and shared data help teams make confident decisions faster without losing control.

• Scaling Oncology Trials Without Losing Momentum

  As oncology programs expand, complexity often replaces momentum. Explore how scaling introduces hidden operational challenges and why anticipating continuity early helps teams stay aligned.

• Why Early Phase Speed Depends On Oncology Expertise

  Early phase oncology speed depends on confident, oncology‑specific decisions made upfront. Learn why scientific expertise, realistic planning, and foresight determine whether programs maintain momentum.

• Unanticipated Roadblocks In Ovarian Cancer Drug Development

  Ovarian cancer trials require specialized strategies that go beyond generic tumor designs. Enhance your program by enabling community referral pipelines, aligning imaging with biomarker assessments, and selecting sites based on verifiable surgical capacity.

• Challenges That Derail Bladder Cancer Trials And How To Anticipate Them Earlier

  From the rapid evolution of standard-of-care benchmarks to the logistical strain of procedure-heavy urology workflows, the path to a successful endpoint is filled with operational friction.

• Early Phase Oncology Site Network: Benefits Of A Personal Touch

  Choose a site network built on partnership — not volume — to drive smoother early-phase oncology trials and deliver better outcomes for sponsors, sites, and patients.

• The Growing Complexity Of Conducting Oncology Trials

  As diversity plans and multi-regional considerations become core to trial design, early-phase oncology programs must navigate a landscape that offers unprecedented opportunity.

• Precision Medicine: Targeted Cancer Therapies

  Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

• Specialized Site Network For Early-Phase Oncology Success

  Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.